JOHNSON & JOHNSON is 44.2x more valuable than Axsome Therapeutics, Inc. by market capitalization ($579.83 B vs $13.13 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | AXSM | JNJ |
|---|---|---|
| Market cap | $13.13 B | $579.83 B |
| US-listed rank | #799 | #20 |
| Revenue (latest FY) | $638.50M | $94.19B |
| Net income (latest FY) | -$183.17M | $26.80B |
| Net margin | -28.7% | 28.5% |
| P/E (trailing FY) | - | 21.6 |
| SEC filings | 634 | 984 |
JOHNSON & JOHNSON is 44.2x more valuable than Axsome Therapeutics, Inc. by market capitalization ($579.83 B vs $13.13 B).
In their latest fiscal years, Axsome Therapeutics, Inc. reported $638.50M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Axsome Therapeutics, Inc. and JOHNSON & JOHNSON, or browse the full rankings.